April 2021

Shorla Press Release

Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia Treatment

Clonmel, Ireland.  April 23, 2021.  Seroba’s portfolio company, Shorla Pharma Limited (‘Shorla’), a specialty pharmaceutical company, has announced that it has submitted, and the U.S. Food and Drug Administration (FDA) has accepted for filing, its application for its SH-111 oncology drug designed to treat T-cell leukemia.  SH-111 is a lifesaving treatment that is often in […]

Shorla Pharma Announces FDA Filing Acceptance and Priority Review for T-cell Leukemia Treatment Read More »

Fusion Round

Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors

Hamilton, ON and Boston.  April 1, 2021.   Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines today announced the appointment of Donald A. Bergstrom, M.D., Ph.D., as a member of the Company’s Board of Directors.  Dr Bergstrom, who currently serves as executive vice president, head of research

Fusion Pharmaceuticals Appoints Donald Bergstrom, M.D., Ph.D., to Board of Directors Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top